Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

Covid-19 in Hematological Malignancies

Epidemiology of COVID-19 Infection in Patients With Hematological Malignancies: A European Haematology Association Survey

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The overall purpose of this project is to better understand the epidemiology of COVID-19 in patients with hematological malignancies (including hematopoietic stem cell transplant recipients) in the different European Countries. The results obtained will allow us to better know the prevalence of this complication in the different categories of patients with hematological malignancies (HMs). In order to attain the objectives previously described we will develop a multicentre, international, observational, retrospective and prospective study of consecutive cases of COVID-19 among HMs. There will be a clinical follow-up of the patients included in this study to observe the survival rate. Data collected form this study will be evaluated with a descriptive analysis.

Who May Be Eligible (Plain English)

Who May Qualify: - Age equal to or greater than 18 years of age. - History of hematological malignancies (acute leukemias, myelodysplastic syndromes, myeloproliferative neoplasms, lymphomas, myeloma, chronic myeloprolipherative disorders) at any stage/status. - Active hematological malignancies at any stage/status. - Diagnosis of hematological malignancy (acute leukemias, myelodysplastic syndromes, myeloproliferative neoplasms, lymphomas, myeloma, chronic myeloprolipherative disorders) at any stage/status. - SARS-CoV-2 positive test (nasopharyngeal, BAL, fecal), documented by Real-Time Reverse Transcriptase (RT)-PCR Diagnostic Panels. Who Should NOT Join This Trial: - Hematological diseases, other than hematological malignancies. - Not tested positive for SARS-CoV-2 - Patients "off therapy" for more than 5 years Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Age equal to or greater than 18 years of age. * History of hematological malignancies (acute leukemias, myelodysplastic syndromes, myeloproliferative neoplasms, lymphomas, myeloma, chronic myeloprolipherative disorders) at any stage/status. * Active hematological malignancies at any stage/status. * Diagnosis of hematological malignancy (acute leukemias, myelodysplastic syndromes, myeloproliferative neoplasms, lymphomas, myeloma, chronic myeloprolipherative disorders) at any stage/status. * SARS-CoV-2 positive test (nasopharyngeal, BAL, fecal), documented by Real-Time Reverse Transcriptase (RT)-PCR Diagnostic Panels. Exclusion Criteria: * Hematological diseases, other than hematological malignancies. * Not tested positive for SARS-CoV-2 * Patients "off therapy" for more than 5 years

Locations (6)

ASST-Spedali Civili
Brescia, Italy
AOU Policlinico Federico II
Naples, Italy
Fondazione Policlinico A. Gemelli IRCCS
Rome, Italy
Istituto Nazionale Tumori Regina Elena IFO
Rome, Italy
Osp. di Circolo-Fondazione Macchi
Varese, Italy
AOUI Verona
Verona, Italy